Journal of Immunotherapy and Precision Oncology最新文献

{"title":"Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review","authors":"Daniel Huff, Shannon Fortin Ensign, Margaret S. Ryan, Jeanne Palmer, Javier Munoz","doi":"10.36401/jipo-23-11","DOIUrl":"https://doi.org/10.36401/jipo-23-11","url":null,"abstract":"ABSTRACT Histiocytic sarcoma (HS) is a rare hematologic malignancy that has historically been treated with lymphoma-based regimens with a median survival of 6 months. We describe a case of a 51-year-old woman who presented with acute back pain and cord compression. She was diagnosed with HS with diffuse skeletal lesions and high expression of programmed death ligand 1 (PD-L1). She was subsequently treated with chemotherapy plus off-label use of pembrolizumab followed by allogeneic stem cell transplantation. Ultimately, patient died in the setting of progression of disease 17 months after her stem cell transplantation and 26 months after her diagnosis. This article also presents a literature review of cases of HS treated with programmed death ligand inhibition.","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"224 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134974828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era.","authors":"Maluki Radford,&nbsp;Hassan Abushukair,&nbsp;Stijn Hentzen,&nbsp;Ludimila Cavalcante,&nbsp;Anwaar Saeed","doi":"10.36401/JIPO-22-36","DOIUrl":"https://doi.org/10.36401/JIPO-22-36","url":null,"abstract":"<p><p><i>HER2</i>-targeted therapy with the <i>HER2</i> monoclonal antibody trastuzumab has achieved impressive outcomes in the first-line settings of patients with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing <i>HER2</i>. However, considering that a substantial proportion of those patients eventually relapses, as well as the relatively limited performance of those agents in second-line settings, a deeper understanding of resistance mechanisms is needed for enhanced guidance for patients' therapeutic selection in the second-line setting and beyond. In this review, we highlight trastuzumab's (<i>HER2</i>-targeting agent) performance in patients with gastric or GEJ cancer, with insight into mechanisms of resistance. We also discuss the new integration of <i>PD-1</i> inhibitor pembrolizumab into the trastuzumab for gastric cancer frontline regimen, the latest addition of trastuzumab deruxtecan to the treatment armamentarium, and the potential of pipeline <i>HER2</i>-targeting approaches and combinations in patients with gastric or GEJ adenocarcinoma.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"150-157"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/45/83/i2590-017X-6-3-150.PMC10448730.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Stage IV Non-Small Cell Lung Cancer with Pembrolizumab in Combination with Platinum-Based Doublet Chemotherapy in Vietnam.","authors":"Khanh Toan Nguyen,&nbsp;To Ta Van","doi":"10.36401/JIPO-23-12","DOIUrl":"https://doi.org/10.36401/JIPO-23-12","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer has been one of the most prevalent cancers worldwide in recent decades. According to the findings of the KEYNOTE-407 (2018) study on patients with stage IV squamous cell lung cancer, the combination of pembrolizumab and chemotherapy in the first-line treatment prolongs overall survival compared with chemotherapy alone. This study aimed to evaluate the efficacy and side effects of treating patients with stage IV non-small cell lung cancer with pembrolizumab in combination with platinum-based doublet chemotherapy.</p><p><strong>Methods: </strong>A retrospective multicenter study on 46 patients at four hospitals in Vietnam between June 2018 and August 2022. Patients received first-line treatment with a protocol of pembrolizumab in combination with platinum-based doublet chemotherapy (pemetrexed plus carboplatin or paclitaxel plus carboplatin). The study's primary endpoints were progression-free survival and safety. The secondary endpoint was overall survival.</p><p><strong>Results: </strong>The median progression-free survival was 11.0 months (95% CI, 7.4-14.7 months). The median overall survival was 23.1 months (95% CI, 18.4-27.8 months). The survival rate of patients after 1 and 2 years was 82.3% and 43.3%, respectively. The most common side effects were anemia and elevated liver enzymes, but they were primarily mild or moderate severity. Progression-free survival did not depend on cancer type based on histology (<i>p</i> = 0.13). The progression-free survival was independent of programmed death ligand-1 expression levels < 50% or ≥ 50% (<i>p</i> = 0.68).</p><p><strong>Conclusion: </strong>Treatment of stage IV non-small cell lung cancer without <i>EGFR</i> and <i>ALK</i> gene mutations with the immunotherapy protocol of pembrolizumab in combination with platinum-based doublet chemotherapy resulted in favorable outcomes without any new safety concerns. A larger sample size and longer follow-up in the future are necessary to yield more complete results.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"133-140"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/80/cd/i2590-017X-6-3-133.PMC10448733.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review.","authors":"Mousa Alali,&nbsp;Maher Saifo","doi":"10.36401/JIPO-22-29","DOIUrl":"https://doi.org/10.36401/JIPO-22-29","url":null,"abstract":"<p><strong>Introduction: </strong>Osimertinib is the treatment of choice for epidermal growth factor receptor (<i>EGFR</i>)-mutated advanced non-small-cell lung cancer (NSCLC). Because of its high price, many low-income countries, such as Syria, cannot provide osimertinib, which makes it difficult to choose the appropriate treatment for these patients. This study aimed to review articles that assessed tyrosine kinase inhibitors (TKIs) for advanced NSCLC and developed an appropriate treatment plan for Syrian patients.</p><p><strong>Methods: </strong>An electronic literature search was conducted of published phase II and III studies that assessed the efficacy of EGFR-TKIs for advanced NSCLC between January 2003 and May 2022.</p><p><strong>Results: </strong>Seventeen articles were reviewed. The results were similar when erlotinib or icotinib was compared with gefitinib. Progression-free survival and overall survival for afatinib and dacomitinib were longer than for gefitinib, with small significant differences. Osimertinib was the only TKI that showed efficacy against the T790M mutation, which showed an improvement over the first- and second-generation TKIs. Osimertinib as a first-line therapy is not cost-effective compared with first- and second-generation TKIs.</p><p><strong>Conclusion: </strong>Osimertinib is the preferred first-line treatment in patients with advanced <i>EGFR-</i>mutated NSCLC. First- and second-generation TKIs are still considered good options, especially in low-income countries that cannot cover the costs of osimertinib.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"140-149"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/33/i2590-017X-6-3-140.PMC10448734.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10482871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.","authors":"Anca Chelariu-Raicu,&nbsp;Sarina A Piha-Paul,&nbsp;Mariana Chavez-MacGregor,&nbsp;Jason Johnson,&nbsp;Raymond Sawaya,&nbsp;Mary Frances McAleer,&nbsp;Alissa Nguyen,&nbsp;Audrey Hartnett,&nbsp;Apostolia M Tsimberidou,&nbsp;Funda Meric-Bernstam,&nbsp;Ecaterina E Dumbrava","doi":"10.36401/JIPO-22-33","DOIUrl":"https://doi.org/10.36401/JIPO-22-33","url":null,"abstract":"<p><p>Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except <i>for BRCA1/2</i> mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"158-161"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/50/i2590-017X-6-3-158.PMC10448731.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoimmune HLA Alleles and Neoepitope Presentation Predict Post-Allogenic Transplant Relapse.","authors":"Andrea Castro,&nbsp;Aaron M Goodman,&nbsp;Zachary Rane,&nbsp;James V Talwar,&nbsp;Garrett M Frampton,&nbsp;Gerald P Morris,&nbsp;Scott M Lippman,&nbsp;Xinlian Zhang,&nbsp;Razelle Kurzrock,&nbsp;Hannah Carter","doi":"10.36401/JIPO-22-19","DOIUrl":"https://doi.org/10.36401/JIPO-22-19","url":null,"abstract":"<p><strong>Introduction: </strong>Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure patients with high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). However, many patients relapse or develop debilitating graft-versus-host disease. Transplant restores T-cell reactivity against tumor cells, implicating patient human leukocyte antigen (HLA)-dependent antigen presentation via the major histocompatibility complex as a determinant of response. We sought to identify characteristics of the HLA genotype that influence response in allo-HSCT patients.</p><p><strong>Methods: </strong>We collected HLA genotype and panel-based somatic mutation profiles for 55 patients with AML and MDS and available data treated at the University of California San Diego Moores Cancer Center between May 2012 and January 2019. We evaluated characteristics of the HLA genotype relative to relapse-free time and overall survival (OS) post-allo-HSCT using univariable and multivariable regression.</p><p><strong>Results: </strong>In multivariable regression, the presence of an autoimmune allele was significantly associated with relapse-free time (hazard ratio [HR], 0.25; <i>p</i> = 0.01) and OS (HR, 0.16; <i>p</i> < 0.005). The better potential of the donor HLA type to present peptides harboring driver mutations trended toward better relapse-free survival (HR, 0.45; <i>p</i> = 0.07) and significantly correlated with longer OS (HR, 0.33; <i>p</i> = 0.01) though only a minority of cases had an HLA mismatch.</p><p><strong>Conclusion: </strong>In this single institution retrospective study of patients receiving allo-HSCT for relapsed AML/MDS, characteristics of an individual's HLA genotype (presence of an autoimmune allele and potential of the donor HLA to better present peptides representing driver mutations) were significantly associated with better outcomes. These findings suggest that HLA type may guide the optimal application of allo-HSCT and merit evaluation in larger cohorts. <b>ClinicalTrials.gov Identifier: NCT02478931</b>.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"127-132"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/e5/i2590-017X-6-3-127.PMC10448732.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10465134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy.","authors":"Sebastian Brito-Orama,&nbsp;Rahul A Sheth","doi":"10.36401/JIPO-22-8","DOIUrl":"https://doi.org/10.36401/JIPO-22-8","url":null,"abstract":"<p><p>Systemically administered immunotherapies have revolutionized the care of patients with cancer; however, for many cancer types, most patients do not exhibit objective responses. Intratumoral immunotherapy is a burgeoning strategy that is designed to boost the effectiveness of cancer immunotherapies across the spectrum of malignancies. By locally administering immune-activating therapies into the tumor itself, immunosuppressive barriers in the tumor microenvironment can be broken. Moreover, therapies too potent for systemic delivery can be safely administered to target location to maximize efficacy and minimize toxicity. In order for these therapies to be effective, though, they must be effectively delivered into the target tumor lesion. In this review, we summarize the current landscape of intratumoral immunotherapies and highlight key concepts that influence intratumoral delivery, and by extension, efficacy. We also provide an overview of the breadth and depth of approved minimally invasive delivery devices that can be considered to improve delivery of intratumoral therapies.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 2","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/ea/i2590-017X-6-2-84.PMC10195020.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Studies Using the MALT1 Inhibitor (<i>S</i>)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer.","authors":"Mauro Di Pilato,&nbsp;Yun Gao,&nbsp;Yi Sun,&nbsp;Amina Fu,&nbsp;Carina Grass,&nbsp;Thomas Seeholzer,&nbsp;Regina Feederle,&nbsp;Irina Mazo,&nbsp;Samuel W Kazer,&nbsp;Kevin Litchfield,&nbsp;Ulrich H von Andrian,&nbsp;Thorsten R Mempel,&nbsp;Russell W Jenkins,&nbsp;Daniel Krappmann,&nbsp;Peter Keller","doi":"10.36401/JIPO-22-18","DOIUrl":"https://doi.org/10.36401/JIPO-22-18","url":null,"abstract":"<p><strong>Introduction: </strong>Regulatory T cells (Tregs) play a critical role in the maintenance of immune homeostasis but also protect tumors from immune-mediated growth control or rejection and pose a significant barrier to effective immunotherapy. Inhibition of MALT1 paracaspase activity can selectively reprogram immune-suppressive Tregs in the tumor microenvironment to adopt a proinflammatory fragile state, which offers an opportunity to impede tumor growth and enhance the efficacy of immune checkpoint therapy (ICT).</p><p><strong>Methods: </strong>We performed preclinical studies with the orally available allosteric MALT1 inhibitor (<i>S</i>)-mepazine as a single-agent and in combination with anti-programmed cell death protein 1 (PD-1) ICT to investigate its pharmacokinetic properties and antitumor effects in several murine tumor models as well as patient-derived organotypic tumor spheroids (PDOTS).</p><p><strong>Results: </strong>(<i>S</i>)-mepazine demonstrated significant antitumor effects and was synergistic with anti-PD-1 therapy in vivo and ex vivo but did not affect circulating Treg frequencies in healthy rats at effective doses. Pharmacokinetic profiling revealed favorable drug accumulation in tumors to concentrations that effectively blocked MALT1 activity, potentially explaining preferential effects on tumor-infiltrating over systemic Tregs.</p><p><strong>Conclusions: </strong>The MALT1 inhibitor (<i>S</i>)-mepazine showed single-agent anticancer activity and presents a promising opportunity for combination with PD-1 pathway-targeted ICT. Activity in syngeneic tumor models and human PDOTS was likely mediated by induction of tumor-associated Treg fragility. This translational study supports ongoing clinical investigations (ClinicalTrials.gov Identifier: NCT04859777) of MPT-0118, (<i>S</i>)-mepazine succinate, in patients with advanced or metastatic treatment-refractory solid tumors.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 2","pages":"61-73"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/11/i2590-017X-6-2-61.PMC10195017.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10208482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Learning From Failure: Negative Trials in Oncology.","authors":"Mirella Nardo,&nbsp;Deniz Can Guven,&nbsp;Aysun Senturk Yikilmaz,&nbsp;Shambhavi Singh,&nbsp;Jibran Ahmed","doi":"10.36401/JIPO-23-X1","DOIUrl":"https://doi.org/10.36401/JIPO-23-X1","url":null,"abstract":"Learning From Failure: Negative Trials in Oncology Mirella Nardo, Deniz Can Guven, Aysun Senturk Yikilmaz, Shambhavi Singh, Jibran Ahmed Department of Investigational Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey Department of Hematology, Denizli Government Hospital, Denizli, Turkey Department of Precision Oncology, Sir H N Reliance Foundation Hospital, Mumbai, India","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 2","pages":"59-60"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/85/1f/i2590-017X-6-2-59.PMC10195015.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstracts Presented at the 2022 Emirates Oncology Conference: November 25-27, 2022, Abu Dhabi, United Arab Emirates.","authors":"Khalid Balaraj","doi":"10.36401/JIPO-22-X6","DOIUrl":"https://doi.org/10.36401/JIPO-22-X6","url":null,"abstract":"s Presented at the 2022 Emirates Oncology Conference November 25-27, 2022, Abu Dhabi, United Arab Emirates J Immunother Precis Oncol. 2023; 6:117–126. DOI: 10.36401/JIPO-22-X6. This work is published under a CC-BY-NC-ND 4.0 International License. The Emirates Oncology Conference (EOC), now in its 10th year, continues to highlight important developments in the fields of cancer prevention and treatment. The Abu Dhabi Health Services SEHA and Tawam Hospital hosted the conference. These organizations are dedicated to offering the UAE top-tier healthcare and ongoing medical education to keep the public informed and ensure that medical experts remain up to date in their fields. The EOC featured significant sessions covering a wide range of topics with globally renowned speakers who kept the audience interested with their illuminating lectures and visual presentations. Breast cancer, hematological malignancies, palliative care, lung cancer, radiation oncology, pediatric oncology, genitourinary, gastrointestinal, and neuro-oncology were some of the topics covered. Over the course of the 3 days, there were about 4000 attendees including physicians, surgeons, researchers, healthcare professionals, and industry representatives from over 40 nations, of which 65% were from the UAE and 35% traveled from the USA, Europe, Middle East, and GCC. Approximately 150 speakers were hosted by EOC; speakers came from the USA, UK, Italy, Spain, France, Germany, Belgium, India, Pakistan, Philippines, Malaysia, Canada, and many regional nations such as Jordan, KSA, Oman, Bahrain, Lebanon, Egypt, and the UAE. In addition, more than 2 dozen abstracts were presented as oral and poster presentations, and the top 14 were chosen to be published in a medical journal as a result of EOC 2022. Selected abstracts are included herein. We are grateful to all members of the scientific and medical community, our organizing team, speakers, delegates and sponsors for their time, efforts, and contributions to making EOC one of the most important scientific events of the year. Dr. Kalid Balaraj Chair of Oncology Centre Tawam Hospital, UAE Journal of Immunotherapy and Precision Oncology 2023 | Volume 6 | Issue 2 | 117 jipoonline.org 118 EOC 2022 Abstracts Conference Proceedings 119 120 EOC 2022 Abstracts Conference Proceedings 121 122 EOC 2022 Abstracts Conference Proceedings 123 124 EOC 2022 Abstracts","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 2","pages":"117-126"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/ad/i2590-017X-6-2-117.PMC10195016.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9505549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}